Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash & Current Investments (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Cash & Current Investments for 7 consecutive years, with $238.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Current Investments rose 153.52% year-over-year to $238.6 million, compared with a TTM value of $172.9 million through Dec 2025, down 58.07%, and an annual FY2024 reading of $412.3 million, up 477.32% over the prior year.
  • Cash & Current Investments was $238.6 million for Q3 2025 at Summit Therapeutics, down from $297.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $648.6 million in Q4 2022 and bottomed at $23.8 million in Q3 2023.
  • Average Cash & Current Investments over 5 years is $183.2 million, with a median of $102.2 million recorded in 2021.
  • The sharpest move saw Cash & Current Investments tumbled 88.99% in 2023, then surged 935.93% in 2025.
  • Year by year, Cash & Current Investments stood at $71.8 million in 2021, then soared by 803.47% to $648.6 million in 2022, then crashed by 88.99% to $71.4 million in 2023, then soared by 477.32% to $412.3 million in 2024, then plummeted by 42.15% to $238.6 million in 2025.
  • Business Quant data shows Cash & Current Investments for SMMT at $238.6 million in Q3 2025, $297.9 million in Q2 2025, and $361.3 million in Q1 2025.